Minimize
 

RTOG 9701 Protocol Information

Minimize
Phase III Randomized Trial of Radiation Therapy Alone versus Concurrent Chemotherapy plus Radiation Therapy for Poor-Risk Stage III Non-Small-Cell Lung Carcinoma
Protocol Documents
Current Version Date: 4/20/1998
Principal Investigator: Bryan R. Leigh, M.D.
Primary Objective:

To determine if the survival rate of poor-risk patients with Stage III NSCLC is improved by adding two cycles of concurrent carboplatin and VP-16 to standard thoracic RT.

Patient Population:

Patients will have a histologically or cytologically proven diagnosis of a single, primary bronchogenic NSCLC (adenocarcinoma, large cell carcinoma, or squamous cell carcinoma). Patients must have either Stage IIIA or Stage IIIB disease.

Target Accrual: 316
Current Accrual:
Status: Terminated
Date: 7/23/1999
Participating Sites:
Case Western Reserve University Cleveland OH
Fox Chase Cancer Center Philadelphia PA
Mainline Health CCOP Wynnewood PA
Mobile Infirmary Medical Center Mobile AL
Northwest Community Hospital Arlington Heights IL
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami FL
University of Wisconsin Hospital and Clinics Madison WI
Updated: 4/8/2011

You must be logged in to view this file.

Login  |  Close

You must be logged in to view this file.

Login  |  Close